Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis.

Ronpichai Chokesuwattanaskul Charat ThongprayoonTanyanan TanawuttiwatWisit KaewputPavida PachariyanonWisit Cheungpasitporn

Published in: Pacing and clinical electrophysiology : PACE (2018)

Among patients with advanced CKD and ESRD, the use of apixaban was associated with lower risk of major bleeding compared to warfarin, and was found to be relatively effective with no excess risk of thromboembolic events.

Keyphrases

end stage renal disease
atrial fibrillation
chronic kidney disease
systematic review
peritoneal dialysis
oral anticoagulants
direct oral anticoagulants
venous thromboembolism
meta analyses
case control
randomized controlled trial